TransMedics Group, Inc. logo
TransMedics Group, Inc. (TMDX)
Compare

TransMedics Group, Inc. (TMDX) Free Cash Flow Yield: 5.31%

popular:market cap|pe ratio|revenue|price history|total return

Is TransMedics Group, Inc.’s free cash flow yield high or low?

TransMedics Group, Inc.'s free cash flow yield of 5.31% is 124% above its 1-year average of 2.37%, near the high end of its 1-year range (0.32%–6.74%).

As of Saturday, June 20, 2026.

Free Cash Flow CAGR|Earnings Yield|Dividend Yield|P/FCF Ratio|All Metrics

TMDX Free Cash Flow Yield Chart

TMDX Free Cash Flow Yield
5.31%+116.73% 6M
Zoom

TMDX Free Cash Flow Yield Metrics

FREE CASH FLOW YIELD

5.31%

FREE CASH FLOW YIELD AVG TTM

N/A

FREE CASH FLOW YIELD AVG 3Y

N/A

FREE CASH FLOW YIELD AVG 5Y

N/A

FREE CASH FLOW YIELD AVG 10Y

N/A

FREE CASH FLOW YIELD AVG 15Y

N/A

FREE CASH FLOW YIELD AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

TMDX Competitors' Free Cash Flow Yield

NAMEMARKET CAPFREE CASH FLOW YIELDTTM3Y5Y
TransMedics Group, Inc. (TMDX)$2.72B5.31%N/AN/AN/A
DENTSPLY SIRONA Inc. (XRAY)vs ›$2.07B5.04%4.99%5.60%5.61%
23andMe Holding Co. (ME)vs ›$15.31MN/A-496.25%-255.12%-171.49%
Bio-Rad Laboratories, Inc. (BIO)vs ›$7.64B4.69%4.52%3.14%2.79%
Hims & Hers Health, Inc. (HIMS)vs ›$7.91B0.94%1.42%1.61%1.61%
Tempus AI, Inc. (TEM)vs ›$8.87BN/A-3.09%-3.23%-3.23%
Charles River Laboratories International, Inc. (CRL)vs ›$8.91B4.32%6.24%5.04%4.15%
Baxter International Inc. (BAX)vs ›$10.27B6.97%3.27%3.94%3.75%
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B5.60%5.84%5.45%8.51%
Revvity, Inc. (RVTY)vs ›$11.16B4.42%4.59%3.05%4.01%

Yield Comparison

FCF Yield

5.31%

Earnings Yield

5.55%

Dividend Yield

N/A

Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100

How FCF Yield is used:

  • Shows free cash flow after capital expenditures relative to market cap
  • Can be compared with earnings yield and dividend yield
  • Can be compared with the company's historical range
  • Can be compared with peers that report positive free cash flow

FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.

TransMedics Group, Inc. Free Cash Flow Yield Formula & Definition

FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

TransMedics Group, Inc. Free Cash Flow Yield FAQ

What is the free cash flow yield for TransMedics Group, Inc. (TMDX)?
The free cash flow yield for TMDX stock is 5.31%.
Is TransMedics Group, Inc.'s free cash flow yield high or low?
TransMedics Group, Inc.'s free cash flow yield of 5.31% is 124% above its 1-year average of 2.37%, near the high end of its 1-year range (0.32%–6.74%).

TransMedics Group, Inc. Free Cash Flow Yield History

DATEFREE CASH FLOW YIELD
2026-06-185.31%
2026-06-175.71%
2026-06-165.52%
2026-06-155.54%
2026-06-125.74%
2026-06-115.68%
2026-06-105.59%
2026-06-095.63%
2026-06-085.88%
2026-06-056.02%
2026-06-045.86%
2026-06-036.00%
2026-06-026.11%
2026-06-016.19%
2026-05-296.22%
2026-05-286.17%
2026-05-275.96%
2026-05-265.93%
2026-05-226.06%
2026-05-216.08%
2026-05-206.15%
2026-05-196.33%
2026-05-186.12%
2026-05-156.62%
2026-05-146.74%
2026-05-136.51%
2026-05-126.54%
2026-05-116.50%
2026-05-086.17%
2026-05-075.74%
2026-05-065.73%
2026-05-054.41%
2026-05-043.36%
2026-05-013.26%
2026-04-303.24%
2026-04-293.31%
2026-04-283.22%
2026-04-273.02%
2026-04-242.94%
2026-04-232.88%
2026-04-222.85%
2026-04-213.00%
2026-04-202.89%
2026-04-172.82%
2026-04-162.99%
2026-04-152.81%
2026-04-142.82%
2026-04-132.88%
2026-04-102.86%
2026-04-092.99%
2026-04-082.99%
2026-04-073.04%
2026-04-063.11%
2026-04-023.24%
2026-04-013.25%
2026-03-313.28%
2026-03-303.46%
2026-03-273.29%
2026-03-263.19%
2026-03-253.10%
2026-03-243.00%
2026-03-232.91%
2026-03-202.87%
2026-03-192.87%
2026-03-182.88%
2026-03-172.62%
2026-03-162.62%
2026-03-132.64%
2026-03-122.69%
2026-03-112.53%
2026-03-102.49%
2026-03-092.42%
2026-03-062.52%
2026-03-052.33%
2026-03-042.21%
2026-03-032.21%
2026-03-022.22%
2026-02-272.25%
2026-02-262.43%
2026-02-252.48%
2026-02-242.37%
2026-02-232.20%
2026-02-202.21%
2026-02-192.23%
2026-02-182.19%
2026-02-172.21%
2026-02-132.28%
2026-02-122.30%
2026-02-112.22%
2026-02-102.13%
2026-02-092.17%
2026-02-062.19%
2026-02-052.28%
2026-02-042.27%
2026-02-032.18%
2026-02-022.21%
2026-01-302.21%
2026-01-292.13%
2026-01-282.10%
2026-01-272.14%
2026-01-262.12%
2026-01-232.19%
2026-01-222.14%
2026-01-212.21%
2026-01-202.09%
2026-01-162.07%
2026-01-152.06%
2026-01-142.09%
2026-01-132.07%
2026-01-122.20%
2026-01-092.16%
2026-01-082.15%
2026-01-072.16%
2026-01-062.23%
2026-01-052.34%
2026-01-022.41%
2025-12-312.43%
2025-12-302.43%
2025-12-292.41%
2025-12-262.38%
2025-12-242.33%
2025-12-232.31%
2025-12-222.29%
2025-12-192.32%
2025-12-182.45%
2025-12-172.43%
2025-12-162.37%
2025-12-152.40%
2025-12-122.34%
2025-12-112.32%
2025-12-102.26%
2025-12-092.20%
2025-12-082.17%
2025-12-052.17%
2025-12-042.14%
2025-12-032.11%
2025-12-022.09%
2025-12-011.97%
2025-11-282.02%
2025-11-262.03%
2025-11-252.03%
2025-11-242.11%
2025-11-212.26%
2025-11-202.39%
2025-11-192.22%
2025-11-182.53%
2025-11-172.61%
2025-11-142.57%
2025-11-132.56%
2025-11-122.48%
2025-11-112.42%
2025-11-102.42%
2025-11-072.48%
2025-11-062.37%
2025-11-052.38%
2025-11-042.42%
2025-11-032.37%
2025-10-312.25%
2025-10-302.18%
2025-10-292.20%
2025-10-280.33%
2025-10-270.32%
2025-10-240.33%
2025-10-230.33%
2025-10-220.36%
2025-10-210.36%
2025-10-200.36%
2025-10-170.36%
2025-10-160.37%
2025-10-150.38%
2025-10-140.38%
2025-10-130.38%
2025-10-100.40%
2025-10-090.38%
2025-10-080.36%
2025-10-070.37%
2025-10-060.38%
2025-10-030.37%
2025-10-020.37%
2025-10-010.37%
2025-09-300.38%
2025-09-290.38%
2025-09-260.38%
2025-09-250.38%
2025-09-240.36%
2025-09-230.35%
2025-09-220.34%
2025-09-190.35%
2025-09-180.35%
2025-09-170.36%
2025-09-160.36%
2025-09-150.37%
2025-09-120.37%
2025-09-110.37%
2025-09-100.40%
2025-09-090.40%
2025-09-080.41%
2025-09-050.41%
2025-09-040.41%
2025-09-030.40%
2025-09-020.38%
2025-08-290.37%
2025-08-280.37%
2025-08-270.36%
2025-08-260.37%
2025-08-250.37%
2025-08-220.36%
2025-08-210.36%
2025-08-200.35%
2025-08-190.35%
2025-08-180.34%
2025-08-150.34%
2025-08-140.33%
2025-08-130.32%
2025-08-120.33%
2025-08-110.34%
2025-08-080.37%
2025-08-070.37%
2025-08-060.36%
2025-08-050.34%
2025-08-040.33%
2025-08-010.35%
2025-07-310.36%
2025-07-300.40%

Related Metrics

Free Cash Flow CAGREarnings YieldDividend YieldP/FCF RatioAll Metrics

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Andover, MA
728 employees
www.transmedics.com
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Waleed H. Hassanein
View full financials